TY - JOUR
T1 - Utility of glucagon stimulation test in type 1 diabetes after pancreas transplantation
AU - Hiratsuka, I.
AU - Suzuki, A.
AU - Kondo-Ando, M.
AU - Hirai, H.
AU - Maeda, Y.
AU - Sekiguchi-Ueda, S.
AU - Shibata, M.
AU - Takayanagi, T.
AU - Makino, M.
AU - Fukami, N.
AU - Itoh, T.
AU - Sasaki, H.
AU - Kusaka, M.
AU - Kenmochi, T.
AU - Hoshinaga, K.
AU - Itoh, M.
PY - 2014/4
Y1 - 2014/4
N2 - Background Despite recent progress of immunosuppressive therapy with newly developed agents, long-term pancreatic graft survival after pancreas transplantation still remains low. Therefore, precise assessment of β-cell function after pancreas transplantation is necessary. Methods Pancreatic β-cell secretory activity was measured by means of the peripheral plasma fasting serum C-peptide (CPR) response to 1 mg of glucagon intravenously in 23 patients after pancreas transplantation. The utility of ΔCPR after injection was compared with other indices that reflect insulin secretion. Results When we performed the test, 6 patients still needed insulin injection after the transplantation. Mean CPR before and after glucagon intravenously were 1.9 ± 0.98 ng/mL and 4.6 ± 2.29 ng/mL, respectively. Fasting serum CPR, secretory unit of islet in transplantation (SUIT) index, and ΔCPR after glucagon injection were significantly different between insulin users and nonusers. During follow-up (501 ± 228 days), 3 patients could stop using insulin, and their increase of CPR (1.8 ± 0.5 ng/mL) was significantly higher than that in continuous insulin users (0.3 ± 0.3 ng/mL). Conclusion Fasting CPR, SUIT index, and ΔCPR after glucagon injection could reflect β-cell function for post-pancreas transplant patients, and glucagon stimulation test could give us additional information to predict insulin-free treatment.
AB - Background Despite recent progress of immunosuppressive therapy with newly developed agents, long-term pancreatic graft survival after pancreas transplantation still remains low. Therefore, precise assessment of β-cell function after pancreas transplantation is necessary. Methods Pancreatic β-cell secretory activity was measured by means of the peripheral plasma fasting serum C-peptide (CPR) response to 1 mg of glucagon intravenously in 23 patients after pancreas transplantation. The utility of ΔCPR after injection was compared with other indices that reflect insulin secretion. Results When we performed the test, 6 patients still needed insulin injection after the transplantation. Mean CPR before and after glucagon intravenously were 1.9 ± 0.98 ng/mL and 4.6 ± 2.29 ng/mL, respectively. Fasting serum CPR, secretory unit of islet in transplantation (SUIT) index, and ΔCPR after glucagon injection were significantly different between insulin users and nonusers. During follow-up (501 ± 228 days), 3 patients could stop using insulin, and their increase of CPR (1.8 ± 0.5 ng/mL) was significantly higher than that in continuous insulin users (0.3 ± 0.3 ng/mL). Conclusion Fasting CPR, SUIT index, and ΔCPR after glucagon injection could reflect β-cell function for post-pancreas transplant patients, and glucagon stimulation test could give us additional information to predict insulin-free treatment.
UR - http://www.scopus.com/inward/record.url?scp=84899567581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899567581&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2013.11.027
DO - 10.1016/j.transproceed.2013.11.027
M3 - Article
C2 - 24767392
AN - SCOPUS:84899567581
SN - 0041-1345
VL - 46
SP - 967
EP - 969
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 3
ER -
